Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.
Nat Cardiovasc Res. 2024 Aug;3(8):899-906. doi: 10.1038/s44161-024-00511-2. Epub 2024 Jul 31.
High-proportion spliced-in (hiPSI) titin truncating variant (TTNtv) carriers have a higher risk of atrial fibrillation and heart failure. However, the role of cardiovascular risk factors in modifying the risk of atrial fibrillation and heart failure attributed to hiPSI TTNtv carriers is unknown. Here, we investigate the role of cardiovascular risk, quantified using the pooled cohort equations (PCEs), in influencing the hazard of outcomes attributed to hiPSI TTNtvs among UK Biobank participants without baseline cardiovascular disease. The cohort was stratified based on hiPSI TTNtv carrier status and cardiovascular risk (low: <5%, intermediate: 5.0-7.5% and high: >7.5%). The primary outcome was a composite of atrial fibrillation, heart failure or death. TTNtv noncarriers with low cardiovascular risk were used as the reference group for all analyses. Among 179,752 participants (median age: 56 (49, 62) years; 57.5% female), the risk of the primary outcome was lower in hiPSI TTNtv carriers with low cardiovascular risk (adjusted hazard ratio: 2.23 (95% confidence interval: 1.62-3.07)) than those with high cardiovascular risk (adjusted hazard ratio: 8.21 (95% confidence interval: 6.63-10.18)). A favorable cardiovascular risk factor profile may partially offset the risk of clinical outcomes among hiPSI TTNtv carriers.
高比例剪接(hiPSI)肌联蛋白截断变异(TTNtv)携带者患心房颤动和心力衰竭的风险更高。然而,心血管危险因素在多大程度上改变 hiPSI TTNtv 携带者发生心房颤动和心力衰竭的风险尚不清楚。在这里,我们研究了心血管风险的作用,使用汇总队列方程(PCE)进行量化,以影响 UK Biobank 参与者中无基线心血管疾病的 hiPSI TTNtvs 归因结局的风险。该队列基于 hiPSI TTNtv 携带者状态和心血管风险(低:<5%,中:5.0-7.5%和高:>7.5%)进行分层。主要结局是心房颤动、心力衰竭或死亡的复合结局。所有分析均以低心血管风险的 TTNtv 非携带者作为参考组。在 179752 名参与者中(中位年龄:56(49,62)岁;57.5%为女性),低心血管风险的 hiPSI TTNtv 携带者发生主要结局的风险较低(校正后的危险比:2.23(95%置信区间:1.62-3.07))比高心血管风险(校正后的危险比:8.21(95%置信区间:6.63-10.18))。有利的心血管危险因素谱可能部分抵消 hiPSI TTNtv 携带者临床结局的风险。